Tepezza Lawsuit Update 2026: Payouts, News, Trials

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.

Latest Update: As of September 1, 2026, no global settlement has been reached in the Tepezza hearing-loss litigation (MDL No. 3079, N.D. Illinois). The most recent confirmed development dates back to October 2025, when the court struck all bellwether trial deadlines following private settlement discussions between the parties — a status conference was then held on January 8, 2026 to address next steps. No new bellwether trial dates have been set since. As of the most recent court filings reviewed, the MDL’s case count stands at roughly 277 pending lawsuits, with quarterly settlement talks reportedly continuing.

Last updated: September 2026

You might also find this useful — Reed-Nelson Lawsuit 2026: Settlement and Payout Guide

The tepezza lawsuit update for 2026 centers on bellwether trial outcomes, growing settlement pressure, and a rapidly closing window for new filings. Thousands of patients who took Tepezza for thyroid eye disease say the drug caused permanent hearing loss. Now they want answers and money.

This article breaks down everything happening in the Tepezza litigation right now. You’ll learn about the MDL status, who qualifies, estimated payouts, filing deadlines, and what evidence you need.

Here’s one number worth knowing: more than 1,800 cases are consolidated in federal court as of early 2026. That number keeps climbing. And with bellwether trials on the horizon, the pressure on Amgen to settle is real.

If you received Tepezza infusions and your hearing changed, this guide was written for you.

Tepezza Lawsuit Update

The Tepezza lawsuit update as of 2026 shows the litigation moving toward its most critical phase yet. Bellwether trials are being selected, discovery is largely complete, and settlement discussions are intensifying behind the scenes.

Cases are consolidated in an MDL (multidistrict litigation) in the Northern District of Illinois. Judge Thomas M. Durkin continues to oversee proceedings. The pace of new filings has not slowed down.

Amgen, which acquired Horizon Therapeutics in late 2023, now carries the defense burden. The company has pushed back on liability claims, but the scientific evidence linking Tepezza to hearing damage has strengthened.

Plaintiffs’ attorneys are optimistic about trial readiness. The next few months will determine whether Amgen comes to the table or risks a jury verdict.

Tepezza Lawsuit News 2026

The biggest Tepezza lawsuit news in 2026 is the acceleration of bellwether trial scheduling. Courts use bellwether trials as test cases to gauge how juries respond to the evidence.

Several cases have been shortlisted for trial. These were chosen because they represent common injury patterns: sudden hearing loss, worsening tinnitus, and permanent auditory damage after Tepezza infusions.

Expert witness reports filed in late 2025 and early 2026 bolster the plaintiffs’ position. Multiple otologists and pharmacologists have submitted testimony connecting teprotumumab to inner ear damage.

• Bellwether cases are expected to go to trial in mid to late 2026
• Expert reports link the drug’s mechanism of action to cochlear cell damage
• Amgen’s motion to exclude certain expert testimony was partially denied
• New filings continue at a rate of approximately 50 to 100 per month

The outcome of the first bellwether trial will shape everything. A plaintiff verdict could push Amgen toward global settlement. A defense win could slow things down.

Either way, 2026 is the year this litigation gets its defining moment.

What Is the Tepezza Lawsuit About

The Tepezza lawsuit is about patients who suffered hearing loss or tinnitus after receiving Tepezza infusions for thyroid eye disease. Plaintiffs allege that Horizon Therapeutics (now Amgen) knew about the hearing risks and failed to warn patients or doctors adequately.

Tepezza (teprotumumab) was FDA-approved in January 2020. It was the first and only drug approved to treat thyroid eye disease, also called TED. Patients typically receive eight infusions over about 21 weeks.

The drug works by blocking insulin-like growth factor 1 receptor (IGF-1R). While effective at reducing eye bulging, this mechanism may also damage hair cells in the inner ear.

Clinical trial data showed hearing-related adverse events. But plaintiffs argue the original drug labeling downplayed these risks significantly. Post-market studies revealed that hearing problems occurred in a much higher percentage of patients than the label suggested.

The lawsuits boil down to one question: did the manufacturer hide or minimize a known risk?

Key Takeaway: The Tepezza litigation in 2026 is entering its make-or-break phase, with bellwether trials approaching and more than 1,800 cases consolidated in federal court.

Tepezza Class Action Lawsuit

The term “Tepezza class action lawsuit” is widely searched, but it requires some clarification. The Tepezza litigation is not structured as a traditional class action. It is an MDL, which works differently.

In a class action, one lawsuit represents an entire group. Everyone gets the same outcome. In an MDL, each person files their own individual case. Those cases are grouped together for pretrial efficiency, but each plaintiff retains their own claim.

This distinction matters a lot for payouts. In a class action, settlements get split among thousands, often resulting in small checks. In an MDL, individual settlements can be much larger because each case is evaluated on its own merits.

• Tepezza cases are part of MDL No. 3079
• Each plaintiff has a separate claim with separate damages
• No certified class action exists in the Tepezza litigation
• Some law firms use “class action” loosely in marketing, which causes confusion

If you’ve been searching for a Tepezza class action, what you’re really looking at is an MDL. And frankly, that’s better for you as an individual plaintiff.

Is There a Tepezza Class Action

There is no certified Tepezza class action as of 2026. The cases are handled through multidistrict litigation, not a class action structure.

Think of it this way. A class action is like everyone riding the same bus to the same destination. An MDL is more like a carpool: you share the road, but each person has their own car and their own route.

The MDL allows pretrial matters like discovery and expert testimony to happen once, saving time and resources. But when it comes to trials or settlements, each case stands alone.

This setup benefits plaintiffs with strong evidence. If your hearing loss is well-documented and directly linked to Tepezza infusions, your case can be valued independently.

Some attorneys may still refer to the Tepezza litigation as a “class action” for simplicity. Don’t let that confuse you. Your claim is your own.

Tepezza MDL Update

The Tepezza MDL update for 2026 shows steady forward progress. MDL No. 3079, centralized in the Northern District of Illinois, continues to grow as new plaintiffs join.

Judge Thomas M. Durkin has set an aggressive schedule for bellwether case preparation. Discovery deadlines have been met, depositions of key Horizon Therapeutics executives have been completed, and expert witness challenges (Daubert motions) have been largely resolved.

One significant development: the court denied Amgen’s attempt to exclude testimony from a leading otolaryngologist who linked teprotumumab to irreversible cochlear damage. That ruling strengthened the plaintiffs’ scientific foundation.

• Discovery phase is substantially complete
• Daubert hearings have concluded with mixed results favoring plaintiffs
• Corporate depositions of former Horizon Therapeutics leadership are on record
• Case management orders are setting the stage for trial

The MDL structure has worked in the plaintiffs’ favor so far. Consolidation allowed attorneys to pool resources and build a stronger collective evidence base. Now the focus shifts to trial preparation and possible global settlement talks.

Key Takeaway: The Tepezza litigation is an MDL, not a class action, which means each plaintiff’s case is valued individually and could result in significantly different payout amounts.

Tepezza Bellwether Trials 2026

Tepezza bellwether trials in 2026 are expected to be the turning point of the entire litigation. These test trials will show both sides what a jury thinks about the evidence.

Bellwether trials serve a specific purpose. Courts select a handful of representative cases and try them first. The results help attorneys and judges gauge the strength of claims. They also create enormous pressure to settle.

Three to four cases have been identified as potential bellwether candidates. These cases feature plaintiffs with varying degrees of hearing loss, different numbers of infusions, and different pre-existing conditions.

If plaintiffs win the first bellwether, Amgen will face immediate pressure to negotiate a global settlement. Defense verdicts, on the other hand, could delay resolution and reduce settlement leverage.

The legal world is watching these trials closely. For plaintiffs, the bellwether phase is where theory becomes reality.

Tepezza Hearing Loss Lawsuit

The Tepezza hearing loss lawsuit is the core injury claim driving this litigation. Patients allege that Tepezza infusions caused sudden or progressive hearing loss that, in many cases, became permanent.

Published research supports these claims. A 2021 study found that 65% of Tepezza patients experienced at least one hearing-related adverse event. Some studies put the number even higher when long-term follow-up was included.

The types of hearing damage reported include:

• Sensorineural hearing loss (damage to inner ear nerve pathways)
• Tinnitus (persistent ringing or buzzing in the ears)
• Hyperacusis (painful sensitivity to everyday sounds)
• Ear fullness or pressure (a feeling of blockage)
• Autophony (hearing your own voice abnormally loud)

Many patients say they were never warned about hearing risks before starting treatment. Their doctors were not warned either. The original Tepezza label mentioned hearing issues only briefly, buried in clinical trial data.

For patients who went from normal hearing to needing hearing aids, the emotional and financial toll is severe. Some describe losing the ability to enjoy music, follow conversations, or work in environments that require clear hearing.

These cases form the backbone of the litigation. Without the hearing injury, there is no lawsuit.

Tepezza Side Effects Lawsuit

The Tepezza side effects lawsuit encompasses all adverse reactions linked to the drug, though hearing damage remains the primary focus. Some plaintiffs report additional injuries beyond hearing loss.

Reported side effects associated with Tepezza include:

• Hearing loss (partial or total)
• Tinnitus (chronic ringing)
• Muscle spasms and cramps
• Nausea and diarrhea
• Hair loss (alopecia)
• Changes in blood sugar levels
• Fatigue and joint pain

While hearing-related injuries carry the strongest legal claims, some attorneys are building cases around the totality of side effects. The argument is that Horizon Therapeutics failed to conduct adequate post-market surveillance and underreported adverse events.

The strongest lawsuits involve hearing damage specifically. If you experienced hearing changes after Tepezza, your claim is likely stronger than one based solely on nausea or muscle cramps.

That said, a pattern of underreported side effects supports the broader failure-to-warn narrative. Every documented reaction adds weight.

Tepezza and Permanent Hearing Loss

Tepezza has been linked to permanent hearing loss in a significant number of patients. Studies show that for some patients, hearing does not recover even after stopping treatment.

A peer-reviewed study published in 2023 followed Tepezza patients for an extended period after their last infusion. Researchers found that while some patients experienced partial recovery, a substantial subset had irreversible sensorineural hearing loss.

This matters for two reasons. First, permanent injuries command higher compensation in litigation. Second, the permanence of the damage undermines any defense argument that the side effects are “temporary and manageable.”

This is also helpful — Live Olympics Lawsuit 2026: Settlement and Filing Update

Patients with permanent hearing loss often need:

• Hearing aids (costing $2,000 to $7,000 per pair)
• Ongoing audiological monitoring
• Possible cochlear implant evaluation
• Speech therapy or communication assistance
• Mental health support for depression and social isolation

The financial burden compounds over a lifetime. A 45-year-old who loses hearing permanently faces decades of device costs, replacement batteries, and follow-up appointments.

For the lawsuit, permanent hearing loss is the most valuable injury category. Plaintiffs with documented, irreversible damage will likely see the highest settlement offers.

Key Takeaway: Permanent hearing loss is the most legally significant injury in Tepezza cases, and patients with documented irreversible damage stand to receive the highest compensation.

Tepezza Lawsuit Eligibility

Tepezza lawsuit eligibility depends on a few straightforward criteria. You may qualify if you received Tepezza infusions and developed hearing problems during or after treatment.

Here are the general eligibility requirements:

• You received at least one Tepezza infusion (most plaintiffs received multiple)
• You developed hearing loss, tinnitus, or other auditory symptoms
• Your hearing issues began during or within months after Tepezza treatment
• You have medical records documenting both the treatment and the hearing damage
• Your case falls within the applicable statute of limitations

You do not need to have completed all eight infusions to qualify. Some plaintiffs stopped treatment early specifically because of hearing side effects.

Pre-existing hearing conditions do not automatically disqualify you. If Tepezza made an existing condition worse, that’s still actionable. The key is showing a clear change after treatment.

If you’re unsure whether you qualify, a case evaluation from an experienced attorney can clarify your standing within minutes.

Tepezza Lawsuit Evidence Needed

The evidence needed for a Tepezza lawsuit includes medical records, audiological test results, and documentation of your treatment timeline. Strong evidence is what separates a high-value case from a weak one.

Here’s what strengthens your claim:

• Audiograms taken before and after Tepezza treatment (this is the gold standard)
• Medical records showing your Tepezza infusion dates and dosages
• ENT (ear, nose, and throat) specialist reports documenting hearing changes
• Records from your prescribing endocrinologist or ophthalmologist
• Personal journals or notes about when symptoms first appeared
• Pharmacy or infusion center records confirming treatment

The single most powerful piece of evidence is a baseline audiogram taken before your first infusion compared to one taken after. This before-and-after comparison makes causation nearly impossible to dispute.

If you don’t have a pre-treatment audiogram, don’t panic. Many Tepezza patients were never given one. Attorneys can work with other forms of evidence to establish that your hearing was normal before treatment.

Start gathering your records now. The sooner you compile documentation, the stronger your case becomes.

How to File a Tepezza Lawsuit

Filing a Tepezza lawsuit starts with contacting an attorney who handles pharmaceutical mass tort cases. The process is simpler than most people expect.

Here’s the typical step-by-step process:

1. Free case evaluation: You share your treatment history and symptoms with a law firm. They assess whether you have a viable claim.
2. Signing a retainer agreement: If the firm accepts your case, you sign an agreement. Most Tepezza attorneys work on contingency, meaning you pay nothing upfront.
3. Gathering records: Your legal team requests medical records, audiograms, and infusion history on your behalf.
4. Filing the complaint: Your attorney files your individual lawsuit, which gets transferred into the MDL.
5. Litigation and discovery: Your case proceeds through the consolidated pretrial process.
6. Settlement or trial: Your case resolves through negotiation or, if necessary, trial.

You do not need to travel to Illinois. Even though the MDL is in Chicago, your attorney handles everything remotely. You may need to attend a deposition, but many are conducted by video.

Contingency fees typically range from 33% to 40% of your settlement. If you don’t win, you owe nothing.

The process is designed to be accessible. You don’t need legal expertise. You just need your records and a willingness to pursue your claim.

Key Takeaway: Filing a Tepezza lawsuit requires medical records and an experienced attorney; most cases are handled on contingency with no upfront cost to the plaintiff.

Tepezza Lawsuit Deadline

The Tepezza lawsuit deadline varies by state. Each state has its own statute of limitations for product liability and personal injury claims, typically ranging from two to four years.

The clock usually starts ticking from one of two points:

• The date of injury (when you first noticed hearing problems)
• The date of discovery (when you learned or should have learned that Tepezza caused your hearing issues)

The discovery rule can extend your deadline if you didn’t immediately connect your hearing loss to the drug. Many patients didn’t realize the connection until media coverage and lawsuits brought attention to the issue.

Do not wait. Even if you think you have time, gathering evidence and filing properly takes weeks. Missing your deadline by even one day can permanently bar your claim.

If you received Tepezza infusions between 2020 and 2024 and have not yet filed, check your state’s deadline immediately. Some windows are closing in 2026.

Tepezza Lawsuit Payout

Tepezza lawsuit payouts have not yet been officially determined, as no global settlement has been reached as of early 2026. However, legal analysts and attorneys have projected estimated payout ranges based on comparable pharmaceutical litigation.

Individual payouts will depend on several factors:

• Severity of hearing loss (mild, moderate, severe, or profound)
• Whether the hearing loss is permanent or partially reversible
• Number of Tepezza infusions received
• Impact on quality of life, career, and daily functioning
• Strength of supporting medical evidence
• Age of the plaintiff at time of injury

These are estimates, not guarantees. Actual payouts will depend on bellwether trial outcomes and settlement negotiations.

For context, the 3M earplug litigation resulted in a $6.01 billion settlement across roughly 300,000 claims. Per-plaintiff payouts varied wildly based on injury severity. Tepezza cases, with far fewer plaintiffs and often more severe injuries, could yield higher individual payouts.

The math favors Tepezza plaintiffs. Fewer cases plus serious injuries typically equals larger individual checks.

Tepezza Settlement Amounts 2026

Tepezza settlement amounts in 2026 will be shaped primarily by bellwether trial verdicts. No global settlement has been announced yet, but the conditions for one are building.

Settlement negotiations in mass tort cases typically accelerate after bellwether results. If juries return substantial verdicts in favor of plaintiffs, Amgen will face a financial incentive to settle rather than litigate thousands of individual cases.

Legal analysts project the following settlement tiers for 2026:

A closely related topic: Zantac Lawsuit Settlement: 2026 Timeline and Payouts

These tiers reflect how most pharmaceutical MDL settlements are structured. Cases are scored based on injury severity, documentation quality, and causation strength.

Amgen reported over $1.9 billion in Tepezza revenue in 2023 alone. The company has the financial capacity to fund a large settlement. The question is whether bellwether outcomes force their hand.

If a settlement is announced in 2026, expect it to take 6 to 18 months for individual payouts to be distributed after the agreement is finalized.

For more context, see Finance Lawsuit April 2026: Settlement and Payout Updates

Tepezza Settlement Timeline

The Tepezza settlement timeline depends on bellwether trial outcomes and Amgen’s willingness to negotiate. Based on the current litigation pace, here is a realistic projected timeline.

Mass tort settlements don’t happen overnight. Even after a deal is reached, there’s a claims process where each plaintiff submits documentation and their case gets scored.

Think of it like a home insurance claim after a hurricane. The disaster happened, the policy is valid, but the adjuster still needs to assess your specific damage before writing a check.

For plaintiffs who file in 2026, the most realistic expectation for receiving money is 2027 or 2028. Cases filed later may take even longer.

Patience matters here. But so does filing early. Cases that are in the system before a settlement is announced are positioned to receive payment faster than those filed at the last minute.

Key Takeaway: While no global Tepezza settlement has been reached yet, bellwether trials in 2026 are expected to trigger serious negotiations, with payouts projected in the range of $50,000 to $2 million depending on injury severity.

Tepezza Lawsuit Compensation

Tepezza lawsuit compensation covers both economic and non-economic damages. Plaintiffs are not just seeking reimbursement for medical costs. They want recognition of the full impact this drug had on their lives.

Economic damages include:

• Cost of hearing aids and replacements ($2,000 to $7,000 every 3 to 7 years)
• Audiological testing and monitoring
• ENT specialist visits
• Lost wages or reduced earning capacity
• Cochlear implant costs (if needed, $30,000 to $50,000+ per ear)
• Future medical expenses over a lifetime

Non-economic damages include:

• Pain and suffering
• Emotional distress
• Loss of enjoyment of life
• Social isolation and relationship strain
• Mental health impacts (depression, anxiety)

In pharmaceutical litigation, non-economic damages often exceed economic ones. A jury that hears a mother describe how she can no longer hear her child’s voice is going to award significant compensation.

Some states cap non-economic damages. Others don’t. Your attorney will factor in your state’s rules when building your case.

The total compensation picture is bigger than most people realize. It’s not just about a hearing aid. It’s about everything that changed when you lost your hearing.

Frequently Asked Questions

How much is the Tepezza lawsuit payout per person in 2026?

Estimated payouts range from $50,000 to over $2 million per person.

The exact amount depends on your injury severity, medical documentation, and case strength.

No global settlement has been announced yet, so these are projections based on comparable litigation.

Is there a class action lawsuit against Tepezza?

No, there is no certified class action for Tepezza.

The cases are handled through multidistrict litigation (MDL No. 3079) in the Northern District of Illinois.

Each plaintiff files an individual claim, which typically results in higher individual payouts than a class action.

What is the deadline to file a Tepezza lawsuit in 2026?

Deadlines vary by state, generally ranging from two to four years from the date of injury or discovery.

Some state deadlines are expiring in 2026 for patients treated between 2020 and 2022.

Check your state’s statute of limitations immediately to avoid losing your right to file.

What side effects qualify for a Tepezza lawsuit?

Hearing loss, tinnitus, hyperacusis, and ear fullness are the primary qualifying side effects.

Permanent sensorineural hearing loss carries the strongest legal claim.

Other side effects like muscle spasms or nausea may support a case but are less likely to succeed on their own.

How long will the Tepezza settlement take?

A global settlement could be announced in late 2026 or 2027, depending on bellwether trial outcomes.

After a settlement is reached, individual payouts typically take an additional 6 to 18 months to process.

Plaintiffs who filed early will generally receive their payments sooner.

This litigation is moving faster than most pharmaceutical mass torts. Bellwether trials in 2026 will set the tone for everything that follows.

If you received Tepezza and experienced hearing changes, now is the time to get your records together and pursue your claim. The window to act is narrowing.

Don’t let a deadline slip by while you wait for more news. The best position to be in when a settlement hits is already inside the courthouse.

Worth reading: Paragard Lawsuit 2026: Payouts, Updates, Eligibility

Worth reading: Depo-Provera Lawsuit 2026: What You Need to Know

Something similar worth reading: Education Lawsuit Last Week: 2026 Payout and Filing Guide

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.